Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-BC1 PET Imaging in Multiple Myeloma
NCT06717113Phase 1Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-MM-BC1 in multiple myeloma (MM) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Diagnostic efficacy of 68Ga-NB381 at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
68Ga-MM-BC1
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06717113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717113.